FDA Grants New Indication to Lumateperone for Bipolar Depression

Lumateperone is now the only FDA-approved drug for depressive episodes associated with bipolar I or II disorder in adults, as monotherapy or an adjunct to lithium or valproate.
FDA Approvals

source https://www.medscape.com/viewarticle/965134?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?